Report MyBio: 2021 China Pharma BD Transactions Annual Report

In recent 5 years 524 (disclosed) cross-border licensing deals occurred with Chinese biotechs and pharmas. The number of cross-border deals keeps increasing each year, with a peak in 2021 when there were 133 in-licensing deals done by Chinese parties. Of these 133 deals, 71 were done with US companies, and 34 with European companies (Source: MyBio
This also means that the Agio Capital Healthcare Vertical in 2021 supported almost 15% of the in-licensing deals done between Chinese and European parties, not included the equity or M&A transactions we were involved in!  
We see this trend growing even more in 2022 and beyond, as Chinese companies increasingly are focusing on European assets to in-license. 

Want to read more about this topic? Click here to read the full report on China Pharma Business Development Transactions.

More on subject(s)   Follow us at LinkedIn

Stay up to date